Ibuprofen Tablets Recalled Due to Failed Impurities and Degradation Specifications
Preferred Pharmaceuticals is recalling 266 bottles of generic ibuprofen tablets due to failed impurities and degradation specifications discovered during stability testing. The affected lots were distributed in California and Nevada.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 3/5 (High).
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall for pharmaceutical product quality failures (impurities and degradation specifications). The rubric applies Score 3 to risk-of-harm products where injury has not yet been reported, which matches this situation.
Plain-English summary
Preferred Pharmaceuticals, Inc. is recalling Ibuprofen Tablets, USP 400mg (generic for Motrin) in 30-tablet bottles due to failed impurities and degradation specifications. The recall involves 266 bottles with lot codes B0223H (expires 5/31/2026) and C3023H (expires 9/30/2026). The product was manufactured by Dr. Reddy's Laboratories in Shreveport, Louisiana, and distributed in California and Nevada.
The product failed impurities and degradation specifications during 18-month stability testing.
Consumers with this product should contact their pharmacist or healthcare provider for guidance.
The recalled product
- Product
- Ibuprofen Tablets, USP 400mg, Generic for Motrin, Pkg Size: 30 tablets per bottle, Mfg: Dr. Reddy's Laboratories, Louisiana, Shreveport, NDC 68788-9110-03.
- Manufacturer
- Preferred Pharmaceuticals, Inc.
- Category
- Drug — Ibuprofen / Tablet
- Hazard
- Affected units
- 266
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot: B0223H
- Exp: 5/31/2026
- C3023H
- Exp: 9/30/2026.
Distribution
Related recalls
Same manufacturer · Preferred Pharmaceuticals, Inc.
See all →- ModeratePreferred Pharmaceuticals Recalls Lidocaine Ointment Due to Content Uniformity Failures
FDA (Drugs) · 2026-10-14
- HighGeri-Care artificial tears lubricant eye drops recalled over sterility assurance
FDA (Drugs) · 2026-04-15
- ModerateOndansetron blister packs recalled because tablets are falling out
FDA (Drugs) · 2025-12-24
- ModerateClindamycin Hydrochloride Capsules Recalled for cGMP Deviations
FDA (Drugs) · 2025-05-07
- HighDuloxetine Delayed-Release Capsules Recalled for Nitrosamine Impurity
FDA (Drugs) · 2024-05-29
Same hazard · impurities
See all →- ModerateCipla Recalls Fosfomycin Tromethamine Due to Impurity Specification Failures
FDA (Drugs) · 2026-10-14
- LowSun Pharmaceutical Recalls Tretinoin Cream Due to Impurity Failures
FDA (Drugs) · 2026-10-14
- LowSun Pharmaceutical Recalls Tretinoin Cream Due to Impurity Failures
FDA (Drugs) · 2026-10-14
- LowSun Pharmaceutical Recalls Tretinoin Cream Due to Impurity Specifications
FDA (Drugs) · 2026-10-14
- LowMacleods Recalls Olanzapine Tablets Due to Impurity Levels
FDA (Drugs) · 2026-09-30
Similar recalls
- HighPrescription Ibuprofen Recalled Due to Failed Impurity Specifications
FDA (Drugs) · 2024-09-04
- HighPrescription Ibuprofen Tablets Recalled for Excessive Unknown Impurities
FDA (Drugs) · 2024-09-04
- HighGeneric Ibuprofen 800mg Recalled Due to Failed Impurity and Degradation Specifications
FDA (Drugs) · 2024-11-13
- HighIBU Prescription Ibuprofen Tablets Recalled for Failed Impurity Specifications
FDA (Drugs) · 2024-09-04
- LowIbuprofen 600 mg tablets recalled for failed tablet specifications
FDA (Drugs) · 2024-11-27
- HighParoxetine Tablets Recalled Due to Out-of-Specification Impurity Levels
FDA (Drugs) · 2023-12-06